Drugs that contain Lenalidomide

1. Drug name - REVLIMID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7855217 CELGENE Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
Nov, 2024

(2 years from now)

US7465800 CELGENE Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
Apr, 2027

(4 years from now)

CN1735415A CELGENE Methods And Compositions Using Immunomodulatory Compounds For The Treatment And Control Of Cancer And Other Diseases
Jan, 2011

(11 years ago)

CN1668296A CELGENE Using Selective Cytokine Inhibitory Drug For Methods And Compositions Of Treating And Controlling Cancer And Other Diseases
Sep, 2011

(11 years ago)

CN101647798A CELGENE Method And Composition For Treating And Processing Cancer And Other Diseases By Using Immunomodulatory Compound
Feb, 2012

(10 years ago)

CN1735412A CELGENE Methods And Compositions By Using Selective Cytokine Inhibitory Drug For Treating And Controlling Cancer And Other Diseases
Aug, 2012

(10 years ago)

CN1822834A CELGENE Methods And Compositions Using Immunomodulatory Compounds For Treating And Processing Cancer And Other Diseases
Sep, 2012

(10 years ago)

CN101316588A CELGENE Methods For Treatment Of Certain Leukemias By Using 3-(4-Amino-1-Oxo-1,3-Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
Jul, 2013

(9 years ago)

CN1981761B CELGENE Using Immunomodulatory Compounds For Treating And Controlling Cancer And Other Diseases In The Application And Composition
Jun, 2017

(5 years ago)

CN1981761A CELGENE Method And Composite For Treating And Controlling Cancer And Other Diseases By Using Immunomodulatory Compound
Jun, 2017

(5 years ago)

CN102675281B CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
Aug, 2018

(4 years ago)

CN102675281A CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
Aug, 2018

(4 years ago)

CN101863878A CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
Aug, 2018

(4 years ago)

CN102060843A CELGENE Polymorphic Form Of 3-(4-Amino-1-Oxo-1, 3 Dihydro-Isoindol-2-Yl)-Piperidine-2, 6-Dione
Aug, 2018

(4 years ago)

CN101838261A CELGENE Polymorphic Form Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
Aug, 2018

(4 years ago)

CN101863878B CELGENE 3 - (4-Amino - -1 - Oxo - -1, 3-Dihydro-Isoindole - -2 - Yl)--2, 6-Polymorph Of Diketone
Aug, 2018

(4 years ago)

CN1871003A CELGENE 3 - (4-Amino - -1 - Oxo - -1, 3-Dihydro-Isoindol - -2 - Yl) - Piperidine - -2, A Polymorphic Form Of 6-Dione
Aug, 2018

(4 years ago)

CN102060843B CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
Aug, 2018

(4 years ago)

CN101838261B CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
Aug, 2018

(4 years ago)

CN1871003B CELGENE 3 - (4-Amino - -1 - Oxo - -1, 3-Dihydro-Isoindole - -2 - Yl)--2, 6-Polymorph Of Diketone
Aug, 2018

(4 years ago)

CN1697655B CELGENE For Methods And Compositions Of Treating And Controlling Cancer And Other Diseases By Using Immunomodulatory Compound
Apr, 2019

(3 years ago)

CN1697655A CELGENE For Methods And Compositions Of Treating And Controlling Cancer And Other Diseases By Using Immunomodulatory Compound
Apr, 2019

(3 years ago)

CN103393681A CELGENE Method And Composition For Treating And Controlling Multiple Myeloma
May, 2023

(7 months from now)

CN103495169B CELGENE Method And Composition For Treating And Controlling Multiple Myeloma Tumor
May, 2023

(7 months from now)

CN102379874B CELGENE Using 3 - (4-Amino - -1 - Oxo - -1, 3-Dihydro-Isoindole - -2 - Yl)--2, 6-Dione For The Treatment And Control Of Multiple Myeloma Method And Composition
May, 2023

(7 months from now)

CN102379874A CELGENE Method For Treating And Controlling Multiple Myeloma By Using 3-(4-Azyl-1-Oxo-1,3-Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Diketone And Composition
May, 2023

(7 months from now)

CN103495169A CELGENE Method And Compositions Using Immunomodulatory Compounds For Treatment And Management Of Cancers And Other Diseases
May, 2023

(7 months from now)

CN103393681B CELGENE For Methods And Compositions For The Treatment And Management Of Multiple Myeloma
May, 2023

(7 months from now)

CN102342938A CELGENE Method And Composition For Treating And Controlling Solid Tumour
May, 2023

(7 months from now)

CN102342938B CELGENE A Method And Composition For Treating And Controlling Solid Tumor
May, 2023

(7 months from now)

EP2105135A3 CELGENE Pharmaceutical Compositions For Treating Cancer
Dec, 2016

(5 years ago)

EP2105135B1 CELGENE Pharmaceutical Compositions For Treating Cancer
Dec, 2016

(5 years ago)

EP2105135A2 CELGENE Pharmaceutical Compositions For Treating Cancer
Dec, 2016

(5 years ago)

EP1505973B1 CELGENE Combinations For Treating Multiple Myeloma
Nov, 2017

(4 years ago)

EP1505973A2 CELGENE Combinations For Treating Multiple Myeloma
Nov, 2017

(4 years ago)

EP1505973A4 CELGENE Methods And Compositions Using Immunomodulatory Compounds For Treatment And Management Of Cancers And Other Diseases
Nov, 2017

(4 years ago)

EP3042659B1 CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione
Mar, 2020

(2 years ago)

EP3042659B8 CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione
Mar, 2020

(2 years ago)

EP3042659A1 CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione
Mar, 2020

(2 years ago)

EP3045175A1 CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione
Mar, 2020

(2 years ago)

EP3045175B1 CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione
Mar, 2020

(2 years ago)

EP3045175B8 CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione
Mar, 2020

(2 years ago)

EP1667682A2 CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
Nov, 2020

(1 year, 10 months ago)

EP1667682A4 CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
Nov, 2020

(1 year, 10 months ago)

EP1667682B1 CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
Nov, 2020

(1 year, 10 months ago)

EP2915533B1 CELGENE Pharmaceutical Compositions For Treating Cancer
May, 2023

(7 months from now)

EP2915533A1 CELGENE Pharmaceutical Compositions For Treating Cancer
May, 2023

(7 months from now)

EP2426118B1 CELGENE Methods Of Making Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
Sep, 2024

(1 year, 10 months from now)

EP3045176A1 CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione
Sep, 2024

(1 year, 10 months from now)

EP2426118A1 CELGENE Methods Of Making Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
Sep, 2024

(1 year, 10 months from now)

EP3045176B1 CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione
Sep, 2024

(1 year, 10 months from now)

EP3045176B8 CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione
Sep, 2024

(1 year, 10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9056120 CELGENE Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine Apr, 2023

(6 months from now)

US7189740 CELGENE Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes Apr, 2023

(6 months from now)

US8404717 CELGENE Methods of treating myelodysplastic syndromes using lenalidomide Apr, 2023

(6 months from now)

US8530498 CELGENE Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione May, 2023

(7 months from now)

US9155730 CELGENE Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent May, 2023

(7 months from now)

US8648095 CELGENE Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor May, 2023

(7 months from now)

US9101621 CELGENE Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation May, 2023

(7 months from now)

US9101622 CELGENE Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone May, 2023

(7 months from now)

US9393238 CELGENE Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent May, 2023

(7 months from now)

US8492406 CELGENE Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione Oct, 2023

(1 year, 3 days from now)

US7968569 CELGENE Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione Oct, 2023

(1 year, 3 days from now)

US7468363 CELGENE Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione Oct, 2023

(1 year, 3 days from now)

US8741929 CELGENE Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas Mar, 2028

(5 years from now)

Treatment: Use of revlimid (lenalidomide) for treatment of patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities; Use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone; Use of revlimid (lenalidomide) for the treatment of previously treated follicular lymphoma in combination with a rituximab product; Use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, as maintenance following autologous hematopoietic stem cell transplantation (auto-hsct); Use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone, wherein those patients have not received previous treatment for multiple myeloma; Use of revlimid (lenalidomide) for the treatment of previously treated marginal zone lymphoma in combination with a rituximab product; use of revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib; use of revlimid (lenalidomide) for the treatment of previously treated follicular lymphoma in combination with a rituximab product; Use of revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG CAPSULE;ORAL Prescription
5MG CAPSULE;ORAL Prescription
10MG CAPSULE;ORAL Prescription
15MG CAPSULE;ORAL Prescription
20MG CAPSULE;ORAL Prescription
25MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.